Spruce Biosciences Bolsters Commercial Leadership with Appointment of Brian Walls as VP, Market Access, and Darren Johnson as VP, Commercial Operations
Spruce Biosciences, a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical needs, has announced the strategic appointments of Brian Walls as Vice President of Market Access and Darren M. Johnson as Vice President of Commercial Operations. These additions to the leadership team come at a critical juncture as the company prepares for a potential commercial launch of its lead investigational therapy for a rare genetic disorder.
The appointments reflect Spruce’s commitment to building a robust commercial infrastructure capable of supporting the anticipated launch of tralesinidase alfa enzyme replacement therapy (TA-ERT), an investigational treatment for Sanfilippo Syndrome Type B (MPS IIIB). As the company transitions from a development-stage organization toward commercialization, the expertise brought by Walls and Johnson is expected to play a pivotal role in ensuring readiness across key commercial functions, including market access, pricing strategy, analytics, and operational execution.
Brian Walls joins Spruce with more than two decades of experience in biopharmaceutical commercial leadership, with a particular focus on market access and payer strategy. Over the course of his career, he has contributed to more than 18 product launches spanning rare and ultra-rare diseases, oncology, neurology, and metabolic disorders. His extensive background in navigating complex reimbursement landscapes and securing patient access to innovative therapies positions him as a valuable asset for Spruce as it prepares to introduce a potential first-in-class treatment.
Most recently, Walls served as Vice President of Market Access at Applied Therapeutics, where he was responsible for designing and implementing the U.S. commercialization access platform for ultra-rare neurology assets. His work there involved building foundational strategies to ensure that highly specialized therapies could reach patients efficiently following regulatory approval. Prior to that role, he held a similar position at Reata Pharmaceuticals, where he led enterprise-wide access strategy for the launch of SKYCLARYS, a treatment for Friedreich’s ataxia. His contributions were instrumental in establishing pricing, reimbursement, and payer engagement strategies that supported a successful product introduction.
Earlier in his career, Walls served as Executive Director of Market Access at Progenics Pharmaceuticals, where he played a key role in securing New Technology Add-on Payment (NTAP) approval for AZEDRA, a radiotherapeutic used in rare cancer treatment. He also held a leadership role at Alexion Pharmaceuticals, where he oversaw U.S. access strategy for the launches of Strensiq and Kanuma, both therapies targeting ultra-rare metabolic disorders, as well as the expansion of Soliris into nephrology indications. His earlier experience includes senior commercial roles at Amgen and GlaxoSmithKline, further broadening his expertise across therapeutic areas and commercialization models.
Darren M. Johnson brings nearly 20 years of experience in commercial operations, analytics, and market planning within the biopharmaceutical industry. His expertise lies in building data-driven commercial infrastructures and preparing organizations for successful product launches, particularly in the rare disease space. At Spruce, he will be responsible for developing the operational backbone needed to support the anticipated commercialization of TA-ERT, including sales operations, forecasting, and strategic planning.
Johnson most recently served as Vice President of Commercial Operations and Analytics at Applied Therapeutics, where he built the company’s commercial data ecosystem from the ground up. Within six months of joining, he established critical functions such as sales operations, pricing strategy, and targeting frameworks, enabling the organization to rapidly scale its commercial readiness. Prior to that, he held a leadership role at Reata Pharmaceuticals, where he was instrumental in market planning and global commercial operations. His contributions supported the successful launch of key products and played a role in the company’s eventual $7.3 billion acquisition by Biogen.
Earlier in his career, Johnson served as Senior Director of Global Commercial Analytics at BioMarin Pharmaceutical, where he led analytics and operations for a global rare disease portfolio with commercial presence in more than 70 countries. He also held positions of increasing responsibility at Genentech, most recently as Group Manager of Forecasting and Business Analysis. His academic credentials include an MBA from Carnegie Mellon University and a Bachelor of Arts in Economics and Japanese Language from the University of California, Berkeley.
The addition of Walls and Johnson underscores Spruce’s strategic focus on assembling a leadership team with deep expertise in rare disease commercialization. According to Dale Hooks, Chief Commercial Officer of Spruce Biosciences, both executives bring highly complementary skill sets that are essential for a successful product launch. Walls’ experience in market access, pricing, and payer engagement, combined with Johnson’s strengths in commercial operations and analytics, creates a comprehensive foundation for the company’s commercial strategy.
Hooks emphasized that both leaders have been involved in some of the most successful rare disease launches in recent years, and their insights will be invaluable as Spruce prepares for a potential launch of TA-ERT. He noted that building a strong commercial infrastructure is critical not only for ensuring regulatory success but also for delivering therapies to patients who urgently need them.
Sanfilippo Syndrome Type B, also known as MPS IIIB, is a rare and devastating genetic disorder characterized by progressive neurological decline. There are currently no approved disease-modifying treatments for this condition, making the development of TA-ERT particularly significant. If approved, the therapy could represent the first treatment option capable of altering the course of the disease, offering hope to patients and families affected by this condition.
Walls expressed enthusiasm about joining Spruce at this important stage, highlighting the opportunity to contribute to the development of a therapy that could have a profound impact on patients’ lives. He noted that building an effective access infrastructure will be essential to ensuring that eligible patients can receive the therapy as quickly as possible following approval. His focus will be on establishing payer relationships, pricing strategies, and reimbursement pathways that support broad and equitable access.
Johnson similarly described the appointment as an opportunity to contribute to a meaningful and high-impact launch. He emphasized the importance of creating a strong commercial foundation that can support not only the initial launch but also the long-term success of the therapy. By leveraging data-driven insights and operational excellence, he aims to ensure that Spruce is fully prepared to meet the needs of patients, healthcare providers, and other stakeholders.
In addition to announcing these leadership appointments, Spruce disclosed that both Walls and Johnson will receive inducement equity awards as part of their employment packages. Each executive will be granted restricted stock units (RSUs) representing 3,500 shares of the company’s common stock, subject to the filing of an effective inducement plan registration statement. These awards, approved by the company’s Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), are designed to align the executives’ interests with those of shareholders.
The RSUs will vest over a four-year period in equal annual installments, contingent upon continued employment with the company. The awards are subject to the terms and conditions of Spruce’s inducement plan and individual grant agreements, reflecting standard practices for executive compensation in the biopharmaceutical industry.
Overall, the appointments of Brian Walls and Darren M. Johnson represent a strategic investment in Spruce Biosciences’ future. As the company moves closer to potential commercialization of TA-ERT, the addition of experienced leaders in market access and commercial operations positions it to navigate the complexities of launching a therapy in the rare disease space. With a strong leadership team in place, Spruce is taking important steps toward delivering a potentially transformative treatment to patients with Sanfilippo Syndrome Type B and advancing its mission to address critical unmet medical needs in neurology.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.
